{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:23:25Z","timestamp":1777649005415,"version":"3.51.4"},"reference-count":74,"publisher":"Informa Healthcare","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2001,9]]},"DOI":"10.1517\/13543784.10.9.1755","type":"journal-article","created":{"date-parts":[[2005,5,4]],"date-time":"2005-05-04T19:43:50Z","timestamp":1115235830000},"page":"1755-1766","source":"Crossref","is-referenced-by-count":20,"title":["Statins in the 21st century: end of the simple story?"],"prefix":"10.1517","volume":"10","author":[{"given":"Sheila A","family":"Doggrell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3197","published-online":{"date-parts":[[2005,2,24]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00525-2"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03500230097036"},{"key":"CIT0003","first-page":"2051","volume":"282","author":"ANSELL BJ","year":"1999","journal-title":"National Cholesterol Education Program. JAMA"},{"key":"CIT0004","first-page":"1383","volume":"344","author":"SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP","year":"1994","journal-title":"Lancet"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00904-1"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.22.2661"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)00910-3"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351401"},{"key":"CIT0011","first-page":"2513","volume":"98","author":"GOLDBERG RB","year":"1998","journal-title":"SACKS FM etal.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels; Subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.2.216"},{"key":"CIT0013","first-page":"839","volume":"98","author":"RIDKER PM","year":"1998","journal-title":"Cholesterol and Recurrent Events (CARE) Investigators. Circulation"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811053391902"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.18.1784"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200008033430502"},{"key":"CIT0018","first-page":"1871","volume":"2000","author":"TONKIN AM","journal-title":"Lancet"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511163332001"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.20.1615"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.24.2340"},{"key":"CIT0024","first-page":"946","volume":"28","author":"BLAUW GJ","year":"1997","journal-title":"A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440330039004"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199011083231901"},{"key":"CIT0027","first-page":"969","volume":"119","author":"BLANKENHORN DH","year":"1993","journal-title":"The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann. Intern. Med."},{"key":"CIT0028","first-page":"959","volume":"89","author":"WATERS D","year":"1994","journal-title":"GLADSTONE P etal.: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation"},{"key":"CIT0029","first-page":"2404","volume":"92","author":"WATERS D","year":"1995","journal-title":"GLADSTONE P etal.: Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. Circulation"},{"key":"CIT0030","first-page":"614","volume":"94","author":"WATERS D","year":"1996","journal-title":"A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. CCAIT Study Group. Circulation"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92082-6"},{"key":"CIT0032","first-page":"1133","volume":"26","author":"PITT B","year":"1995","journal-title":"ELLIS SG etal.:Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J. Am. Coll. Cordial"},{"key":"CIT0033","first-page":"2528","volume":"91","author":"JUKEMA JW.","year":"1995","journal-title":"VAN BOVEN JH et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symtomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation"},{"key":"CIT0034","first-page":"226","volume":"18","author":"BESTEHORN HP","year":"1997","journal-title":"The Multicenter coronary Intervention Study (CIS). Eur. Heart. J."},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00346-9"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701163360301"},{"key":"CIT0037","first-page":"3241","volume":"99","author":"CAMPEAU L","year":"1999","journal-title":"NHLBI post coronary bypass graft clinical trial. Post CABG Trial Investigators. Circulation"},{"key":"CIT0038","first-page":"157","volume":"102","author":"KNATTERUD GL","year":"2000","journal-title":"CAMPEAU L etal.: Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.15.1748"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(91)90002-Y"},{"key":"CIT0041","first-page":"1331","volume":"33","author":"WEINTRAUB WS","year":"1994","journal-title":"Lovastatin Restenosis Trial Study Group. N Engl. J. Med."},{"key":"CIT0043","first-page":"1393","volume":"20","author":"KLEEMANN A","year":"1999","journal-title":"Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial. Eur. Heart. J."},{"key":"CIT0044","first-page":"863","volume":"30","author":"BERTRAND ME","year":"1997","journal-title":"The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty. J. Am. Coll. Cordial"},{"key":"CIT0045","first-page":"58","volume":"21","author":"SERRUYS PW","year":"1999","journal-title":"JACKSON G etal.: A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur. Heart J."},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.6.2519"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199502233320801"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.20.3.737"},{"key":"CIT0049","first-page":"3227","volume":"99","author":"DUPUIS J","year":"1999","journal-title":"The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1378\/chest.118.3.756"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1161\/hc2901.094094"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)00637-6"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)01004-3"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(90)90117-2"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)78556-1"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(94)90151-1"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(95)05757-9"},{"key":"CIT0058","first-page":"172","volume":"92","author":"LACOSTE L","year":"1995","journal-title":"Correction of increased thrombogenic potential with cholesterol reduction. Circulation"},{"key":"CIT0059","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1055\/s-0037-1613893","volume":"83","author":"DANGAS G","year":"2000","journal-title":"Thromb. Haemost."},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00023-6"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(00)00397-X"},{"key":"CIT0062","first-page":"197","volume":"3","author":"PUCCETTI L","year":"1999","journal-title":"Eur. Rev Med. Pharmacol ScL"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00745-6"},{"issue":"69","key":"CIT0064","first-page":"1830\u2013","volume":"2000","author":"HOLSCHERMANN H","year":"1836","journal-title":"Transplantation"},{"key":"CIT0065","first-page":"2113","volume":"20","author":"TOMAS M","year":"2000","journal-title":"Atter\/ostler. Th1-0171b. V3SC. Biol."},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704033361401"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.5.425"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.20.2007"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a008963"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503093321003"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07591-5"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199408183310701"},{"key":"CIT0073","first-page":"230","volume":"100","author":"RIDKER PM","year":"1999","journal-title":"The Cholesterol and Recurrent Events (CARE) Investigators. Circulation"},{"key":"CIT0074","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2001.115297"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00950-5"},{"key":"CIT0076","first-page":"1959","volume":"344","author":"RIDKER PM","year":"2001","journal-title":"CLEARFIELD Metal.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Erigl. J Med."},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)01400-4"},{"key":"CIT0078","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood.V84.7.2068.2068","volume":"84","author":"CARLOS TM","year":"1994","journal-title":"Blood"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1038\/89058"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00132-0"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.10.9.1755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T06:39:07Z","timestamp":1586241547000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.10.9.1755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9]]},"references-count":74,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2005,2,24]]},"published-print":{"date-parts":[[2001,9]]}},"alternative-id":["10.1517\/13543784.10.9.1755"],"URL":"https:\/\/doi.org\/10.1517\/13543784.10.9.1755","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9]]}}}